Search
Displaying results 31 to 40 of 61.
Partner
Partner About us A strong network for the requirements of Individualized Infection Medicine. The embedding of CiiM in the region's existing research network ensures access to patients, interdisciplinary expertise and state-of-the-art technology. Through the…
Team
Team Since its foundation in 2015, the CiiM has grown continuously and coordinative and administrative teams have been created alongside the research groups . Management Prof Dr Yang Li CiiM Director - CiiM Computational Biology for Individualised Medicine…
Personalised Immunotherapy
Our motivation is to address fundamental questions of human immunology and translate them into personalized therapies and diagnostics. Specifically, our laboratory discovers new applications of antibodies and B cells to treat and prevent human infectious diseases. Effective vaccines against some viruses that escape antibody responses remain elusive. To tackle this challenge, we develop methods to better understand B cell responses, the cells that produce antibodies. We design tailored vaccines and provide novel solutions for infection diagnostics.
Research groups
Research The groups at CiiM Four research groups of the HZI and the MHH are currently directly assigned to CiiM and are housed in TWINCORE until the new building is commissioned. In addition, other professorships at MHH (some as joint appointments with HZI)…
Immunology of Viral Hepatitis and Infections in Liver Cirrhosis
Hepatitis viruses A-E pose a major health challenge worldwide. Acute infections with hepatitis B (HBV), C (HCV), D (HDV) or E (HEV) can progress to chronic hepatitis and lead to liver cirrhosis and hepatocellular carcinoma. Chronic viral hepatitis affects more than 350 million people worldwide. While direct-acting antiviral drugs provide a cure for chronic hepatitis C, the long-term effects on the immune system after the infection is cured are not fully understood. While direct-acting antiviral nucleos(t)ide analogues can treat chronic hepatitis B, complete cure is rare. Innovative approaches, particularly modulation of the immune response to HBV, hold promise for a cure. Chronic hepatitis D is always a co-infection with HBV and thus concepts to cure HBV will also target HDV. In chronic hepatitis E, which is unique in immunocompromised patients such as organ transplant patients, enhancing the immune response against HEV may be a novel strategy. In people with cirrhosis of the liver, regardless of the cause, the immune system is compromised and susceptibility to infection is increased. In particular, bacterial infections of the peritoneal cavity due to ascites contribute significantly to disease progression. Our research group focuses on understanding immune responses to hepatitis viruses and developing biomarkers to better stratify patients for new therapeutic strategies to modulate the host immune system in the effort to combat chronic viral hepatitis. In addition, we are exploring the mechanisms underlying immunodeficiency in liver cirrhosis and investigating immunomodulation strategies to improve survival in these vulnerable patients.
D-Solve
D-SOLVE EU-Project Logo D-SOLVE The path to personalised hepatitis D treatment Hepatitis D is by far the most severe form of chronic viral hepatitis frequently leading to liver failure, hepatocellular carcinoma and death. However, there is very limited…
Prof Dr Yang Li
Prof Dr Yang Li CiiM Director - CiiM +49 511 220027200 E-Mail Yang Li has headed the Department of Computational Biology for Individualised Medicine at the CiiM and the HZI since 2019 and was also appointed Director of the CiiM. The focus of her research is…
Prof Dr Markus Cornberg
Prof Dr Markus Cornberg CiiM Director - CiiM +49 511 532 6821 E-Mail Markus Cornberg is W3-Professor Infectious Diseases with a focus on Hepatology and Deputy Director of the Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology…
Update Construction
Update Construction Location & Building Construction schedule and current work in progress In the following, we provide information on the planned construction process and current work in progress. Status August 2024 Current work in progress until December…
